{"product_id":"ambu-five-forces-analysis","title":"Ambu Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAmbu faces moderate supplier power, high buyer expectations for device performance and cost, intense rivalry from med-tech incumbents, and a growing threat from innovative substitutes in digital diagnostics; barriers to entry are mixed due to regulatory hurdles but attractive margins. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Ambu’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmbu depends on medical-grade plastics, precision electronics, and HD optical sensors for single-use endoscopes, and only about 10–15 suppliers globally meet EU and FDA standards, giving suppliers moderate leverage; in 2024 Ambu reported 23% gross margin pressure from component cost inflation, and a 6-week microchip shortage in Q2 2024 delayed production by ~8%, raising per-unit costs by an estimated DKK 12—supply disruptions directly hit timelines and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching Costs for Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe technical specs for Ambu medical devices are tightly regulated and embedded in production, so switching component suppliers triggers extensive testing and re-validation for FDA and CE Mark compliance; studies show regulatory requalification can take 6–18 months and cost $0.5–$2.5M per component. These high switching costs limit Ambu’s vendor mobility and raise supplier bargaining power, contributing to supplier-driven margin pressure—Ambu reported 2024 gross margin of 60.2%, sensitive to input-cost shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFluctuations in global logistics and tighter availability of petroleum-based polymers raised Ambu’s materials cost by an estimated 6–9% in 2024–2025, driven by shipping delays and polymer price spikes (PVC\/TPU up ~18% YoY by Q3 2025). Geopolitical tensions and EU\/US plastic restrictions tightened markets late 2025, forcing Ambu to hold strategic reserves covering ~3–4 months of production or secure multi-year supplier contracts to cap input-price exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Concentration in High-Tech Optics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe market for advanced CMOS sensors and miniature lighting for endoscopy is concentrated among a few specialist firms—Sony, OmniVision, and Osram\/ams OSRAM supply key modules—giving suppliers high bargaining power over price and lead times; Ambu reported components cost pressure contributing to gross margin headwinds in 2024, with semiconductor inflation adding ~1–2 percentage points to COGS. Ambu relies on collaborative partnerships, co-development and multi-year supply agreements to secure priority access and mitigate single-supplier risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew dominant suppliers: Sony, OmniVision, ams OSRAM\u003c\/li\u003e\n\u003cli\u003eComponent-driven margin impact: ~1–2 pp COGS rise (2024)\u003c\/li\u003e\n\u003cli\u003eStrategy: co-development, multi-year contracts\u003c\/li\u003e\n\u003cli\u003eRisk: single-supplier disruption can delay product launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe manufacturing of Ambu’s precision medical devices relies on specialized production hubs and scarce biomedical engineers; OECD data shows average manufacturing wages rose ~6% in 2024 in key regions, raising unit labor costs.\u003c\/p\u003e\n\u003cp\u003eRising labor costs and limited specialist availability push outsourced R\u0026amp;D and contract manufacturing rates up, increasing Ambu’s COGS and operating margins pressure—labor intensity elevates bargaining power of these suppliers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6% avg wage rise (2024, OECD)\u003c\/li\u003e\n\u003cli\u003eShortage of biomedical engineers = higher contractor rates\u003c\/li\u003e\n\u003cli\u003eOutsourced R\u0026amp;D adds to COGS and margin pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration lifts Ambu margin risk—requalification costly, buffer stocks used\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-high power: few qualified vendors (10–15), concentrated CMOS\/LED suppliers (Sony, OmniVision, ams OSRAM), and high switching\/validation costs (6–18 months, $0.5–$2.5M) raised Ambu’s 2024 gross-margin sensitivity (60.2%)—component inflation added ~1–2 pp COGS; Ambu uses co-development and multi-year contracts plus 3–4 months buffer stocks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified suppliers\u003c\/td\u003e\n\u003ctd\u003e10–15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e60.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS impact (2024)\u003c\/td\u003e\n\u003ctd\u003e+1–2 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRequalification cost\/time\u003c\/td\u003e\n\u003ctd\u003e$0.5–$2.5M \/ 6–18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUncovers key competitive drivers, supplier and buyer power, entry barriers, substitutes, and rival intensity tailored to Ambu’s market position, highlighting disruptive threats and strategic levers to protect and grow market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Ambu Porter’s Five Forces snapshot—visualize supplier, buyer, rivalry, entrant, and substitute pressures at a glance to speed strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge hospital networks and gpos account for a large share of ambu revenue in about device purchases flowed through consolidated buyers forcing to accept volume-based pricing secure contracts.\u003e\n\u003cpby continued hospital mergers system concentration rose to of acute care beds increased buyer leverage enabling discounts often in the mid-teens and pressuring ambu gross margins which were\u003e\n\u003c\/pby\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Value-Based Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals now prioritize total cost of ownership over upfront price, and Ambu’s single-use devices—claimed to cut reprocessing and cross-contamination costs—fit that demand; buyers still push for hard proof: a 2023 NHS review found single-use endoscopes can save £150–£600 per procedure when accounting for infection and reprocessing, but procurement panels demand transparent clinical and economic data linking Ambu’s devices to similar or better outcomes and lower lifecycle costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs between Single-Use Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSwitching between single-use endoscope brands is quick for clinicians, since workflows and sterilization steps are already altered compared with reusables; hospitals can swap suppliers with days to weeks of retraining.\u003c\/p\u003e\n\u003cp\u003eIf a competitor matches Ambu’s clinical performance at a lower price, procurement teams can shift volumes fast—pressure intensified because 2024 US hospital device purchasing showed 28% of contracts re-competed annually. \u003c\/p\u003e\n\u003cp\u003eThat low switching cost forces Ambu to protect margins via competitive pricing, service SLAs, and supply-chain reliability; Ambu reported 2024 disposable endoscope gross margin around mid-40s percent, so small price moves matter. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBudgetary Constraints in Public Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cppublic healthcare systems face strict annual budgets and austerity in oecd health spending growth slowed to pushing hospitals favor low-cost devices or demand rebates up on procurements.\u003e\n\u003cpambu must offer flexible financing leasing or bundled consumable-plus-device contracts to win tenders and lock in volume-based rebates over years.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospitals demand 20–30% rebates\u003c\/li\u003e\n\u003cli\u003eOECD health spend growth 1.5% (2024)\u003c\/li\u003e\n\u003cli\u003eUse 3–5 year bundled contracts\u003c\/li\u003e\n\u003cli\u003eOffer leasing\/financing options\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pambu\u003e\u003c\/ppublic\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformed Clinical Decision Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern physicians and hospital procurement teams use extensive comparative data and peer-reviewed studies—purchase decisions increasingly hinge on clinical efficacy and device specs, with 72% of US hospitals citing clinical outcomes as top purchase criteria in 2024.\u003c\/p\u003e\n\u003cp\u003eThis transparency forces Ambu to compete on innovation and clinical evidence, not brand alone; R\u0026amp;D spend rose to DKK 1.1bn in 2024 to support product differentiation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e72% hospitals: clinical outcomes priority (2024)\u003c\/li\u003e\n\u003cli\u003eAmbu R\u0026amp;D: DKK 1.1bn (2024)\u003c\/li\u003e\n\u003cli\u003eDecisions driven by peer-reviewed data and specs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ clout squeezes Ambu margins—60% purchases via GPOs, 20–30% rebates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphospitals and gpos drive buyer power of device purchases flow through consolidated buyers in ambu into mid-teen discounts rebates that pressure margins margin company-wide disposable endoscopes mid-40s demand clinical proof cite outcomes as top criterion can switch suppliers days so uses year bundles leasing r\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePurchases via consolidated buyers\u003c\/td\u003e\n\u003ctd\u003e~60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospital concentration (acute beds)\u003c\/td\u003e\n\u003ctd\u003e55% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (company)\u003c\/td\u003e\n\u003ctd\u003e52% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisposable endoscope margin\u003c\/td\u003e\n\u003ctd\u003eMid-40s% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals prioritizing outcomes\u003c\/td\u003e\n\u003ctd\u003e72% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eDKK 1.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical rebates demanded\u003c\/td\u003e\n\u003ctd\u003e20–30% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/phospitals\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAmbu Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Ambu Porter Five Forces analysis you'll receive immediately after purchase—no placeholders, no mockups.\u003c\/p\u003e\n\u003cp\u003eThe document displayed is the full, professionally formatted file—ready to download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final deliverable: the same comprehensive analysis will be available to you instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746898194809,"sku":"ambu-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ambu-five-forces-analysis.png?v=1772192982","url":"https:\/\/matrixbcg.com\/products\/ambu-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}